title: [Multiple sclerosis. What about treatment with monoclonal antibodies?].
authors.affiliation: Service de neurologie A, centre de coordination EDMUS pour la sclérose en plaques, hôpital neurologique Pierre-Wertheimer, CHU de Lyon, 69677 Bron Cedex. romain.marignier@chu-lyon.fr
authors.forename: Romain
authors.initials: R
authors.lastname: Marignier
authors.forename: Christian
authors.initials: C
authors.lastname: Confavreux
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D007155:Immunologic Factors; D000069442:Natalizumab; D000074323:Alemtuzumab; D000069283:Rituximab; D000077561:Daclizumab